Journal of Ect· 2026Q2
Anti-inflammatory Effect of Electroconvulsive Therapy and Association Between Brain-Derived Neurotrophic Factor Increases and Nonrelapse
- 0citations
- Q2SCImago
- 2026year
Short summary
Electroconvulsive therapy (ECT) reduces inflammation markers (soluble IL-2 receptor, EPA, DHA) and shows differential effects on brain-derived neurotrophic factor (BDNF) based on relapse status, with increases in BDNF linked to a lower risk of relapse after 1 year.
AI-generated from the title and abstract; the full text is not read.
Key points
- ECT treatment led to a significant decrease in serum soluble interleukin-2 receptor levels.
- ECT increased serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), indicating an anti-inflammatory effect.
- Serum BDNF levels increased in patients who did not relapse but decreased in those who did over a 1-year follow-up.
- 48.1% of patients achieved remission after ECT, with 37.0% relapsing within 1 year.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: Electroconvulsive therapy (ECT) is effective for severe psychiatric disorders, but relapse after a successful acute course of ECT remains common. Identification of biological predictors of relapse is therefore clinically important. In this exploratory prospective study, we investigated changes in inflammatory and neurogenesis-related biomarkers following an acute course of ECT, and examined their association with relapse during 1-year follow-up. METHODS: Enrolled were 30 patients with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorders who received their first acute course of bitemporal ECT. Clinical assessments and venous blood sampling were conducted before and after the ECT course. We measured serum inflammatory markers, anti-inflammatory factors, and brain-derived neurotrophic factor (BDNF). Relapse was prospectively evaluated using monthly Clinical Global Impression-Severity assessments over 1 year. Repeated-measures analyses were performed to examine biomarker changes and their interaction with relapse status. RESULTS: Following the acute ECT course, 48.1% of patients achieved remission, and 37.0% experienced relapse during 1-year follow-up. ECT was associated with a significant decrease in serum soluble interleukin-2 receptor levels and significant increases in eicosapentaenoic acid and docosahexaenoic acid, indicating an anti-inflammatory effect. Notably, serum BDNF levels increased in the nonrelapse group but decreased in the relapse group, with a significant time-by-relapse interaction. CONCLUSION: An acute course of ECT is associated with anti-inflammatory biological changes and differential modulation of serum BDNF. Increases in BDNF after ECT may be linked to a reduced risk of relapse, suggesting that serum BDNF could be a potential prognostic biomarker for long-term outcomes following ECT.
The authors' abstract, as published at the source. Journal of Ect, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Psychiatry and Mental health
Psychiatry and Mental healthMedicine